Las organizaciones aquí firmantes, presentamos este documento de propuestas con el objetivo de poder establecer plataformas activas y de carácter permanente que permitan de manera conjunta encontrar soluciones efectivas entre las autoridades públicas competentes, representantes políticos y todos los colectivos pertenecientes al ámbito de las enfermedades raras, minoritarias o poco frecuentes y, así, poder defender, promover y mejorar la calidad de vida de los 3 millones de personas afectadas por estas enfermedades en España.
|
Estos trabajos han sido presentados en la 12th HHT International Scientific Conference, Croatia:
Poster: Venous Thromboemboiism In Patients With Hemorrhagic Hereditary Telangiectasia
- Autores: Riera—Mestre A; Gomez-Del Olmo V; Mora Lujan JM; Sénchez R; Del Toro J; Falga C; Mahe I; Valero B; Trujillo-Santos J; Monreal M
- Presentado por: Antoni Riera-Mestre
Poster: ischemic Stroke Or Brain Abscess In Patients With Hemorrhagic Hereditary Telangiectasia
|
Autores: Alfons Macaya, Roser Torrab, en representación del Grupo Español Multidisciplinar de Expertos en Complejo Esclerosis Tuberosa (GEM-CET).
Med Clin 2016;147:211-6
|
BACKGROUND: Tuberous sclerosis complex is highly variable in clinical presentation and findings. Disease manifestations continue to develop over the lifetime of an affected individual. Accurate diagnosis is fundamental to implementation of appropriate medical surveillance and treatment. Although significant advances have been made in the past 15 years in the understanding and treatment of tuberous sclerosis complex, current clinical diagnostic criteria have not been critically evaluated or updated since the last clinical consensus conference in 1998.
|
Both male/female patients with Fabry disease (FD) may receive enzyme replacement therapy (ERT). Previously published analyses of the Fabry Outcome Survey (FOS; Shire-sponsored) database suggested gender differences in timing of ERT initiation. We assessed alignment of criteria for ERT initiation in the Spanish adult population included in FOS with recommendations of a Spanish national consensus. This retrospective analysis examined baseline clinical data of 88 adults (49 females) enrolled in the FOS database up to August 2014.
|
We report data from a prospective, observational study (ZAGAL) evaluating miglustat 100mg three times daily orally. in treatment-naïve patients and patients with type 1 Gaucher Disease (GD1) switched from previous enzyme replacement therapy (ERT). Clinical evolution, changes in organ size, blood counts, disease biomarkers, bone marrow infiltration (S-MRI), bone mineral density by broadband ultrasound densitometry (BMD), safety and tolerability annual reports were analysed. Between May 2004 and April 2016, 63 patients received miglustat therapy; 20 (32%) untreated and 43 (68%) switched.
|
Background and objective: The transition process from paediatric to adult care is a subject of great interest in recent years, especially in chronic diseases with childhood onset, such as inborn errors of metabolism (IEM). Advances in diagnosis and treatment of these diseases have improved their prognosis, with a high number of patients with IEM who currently reach adult age and need to be attended to by non-paediatric professionals.
|
Autores:
F.J. García-Gómeza, I. Acevedo-Bañeza, R. Martínez-Castilloa, J.L. Tirado-Hospitala, J.I. Cuenca-Cuencaa, V.M. Pachón-Garrudoa, R.M. Álvarez-Péreza, R. García-Jiméneza, E. Rivas-Infanteb, J.S. García-Morilloc, I. Borrego-Doradoa
|
|
|
|
